Salubris Pharmaceuticals

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

Retrieved on: 
Thursday, July 13, 2023
The Elements of Style, The Carlyle Group, Goldman Sachs, Hangzhou, Specialised Technical Committees of the African Union, Law, Stock exchange, Special, Attention, Part, Economics, Salubris Pharmaceuticals, Phi Beta Kappa, Business administration, HKEX, Investment, Harvard Business School, Security (finance), General Atlantic, Ageing, Smith College, Master of Business Administration, HK, Management, Property management

The Board of Directors of HUTCHMED (the “Board”) is of the view that the appointment of Ms Yang would provide significant benefits to HUTCHMED taking into consideration her experience in biotechnology company management, business strategy, capital markets and mergers and acquisitions.

Key Points: 
  • The Board of Directors of HUTCHMED (the “Board”) is of the view that the appointment of Ms Yang would provide significant benefits to HUTCHMED taking into consideration her experience in biotechnology company management, business strategy, capital markets and mergers and acquisitions.
  • Carlyle owns approximately 4.7% of the ordinary shares of HUTCHMED, through its affiliate CA Fern Parent.
  • Save for her role with Carlyle, she does not have any relationship with any Directors, senior management or substantial or controlling shareholders of HUTCHMED.
  • Mr Simon To, Chairman of HUTCHMED, said: “The Board warmly welcomes the appointment of Professor Peters as Special Advisor to the Technical Committee, and looks forward to working with her.

Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates

Retrieved on: 
Tuesday, March 28, 2023
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Salubris Pharmaceuticals, Clinical trial, Northwest Biotherapeutics, Pharmacokinetics, Therapy, Heart failure, Biomarker, Safety, Pharmaceutical industry, Dietary supplement, Heart failure with preserved ejection fraction

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

Key Points: 
  • Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • The financing will also support the ongoing Phase 1/2 trial of JK08 in solid tumors and advance JK06, a pre-clinical biparatopic antibody-drug conjugate, into an initial Phase 1/2 study.
  • “We’re thrilled about the progress we made in 2022, particularly completing enrollment in the Phase 1b study of JK07 in HFrEF.
  • The study achieved its objective of characterizing the safety and activity of the molecule and defining the therapeutic window.

Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction

Retrieved on: 
Wednesday, September 7, 2022
Neurology, Cardiology, Biotechnology, Oncology, General Health, Health, Genetics, Other Health, NYHA, Research, Safety, Pharmacokinetics, Northwest Biotherapeutics, NK, Neuregulin, D90, Toxicity, Immunoglobulin G, Heart failure, ADCC, Salubris Pharmaceuticals, Ipilimumab, Immunosuppression, Quality of life, Cohort, Patient, Therapy, Neurodegeneration, Șaeș, Journal of the American College of Cardiology, Biomarker, Clinical trial, D30, Pharmaceutical industry, Vaccine, Heart, EF

Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.

Key Points: 
  • Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.
  • We are also excited to now be recruiting for the first clinical trial with our IL15-CTLA4 antibody fusion, JK08, and we expect to share initial data in 2023.
  • JK08 was designed based on clinical studies from both individual molecules, which together portend synergistic effects in an antibody fusion construct.
  • A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 13) in Patients With Systolic Dysfunction and Heart Failure.

Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer

Retrieved on: 
Monday, May 23, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Inflammation, Company, Health, Research, Ipilimumab, Medical writing, Patient, Pharmacovigilance, Immunosuppression, Pharmacokinetics, Salubris Pharmaceuticals, Health care, HER3, Heart, Neurodegeneration, Pediatrics, Industry, Cohort, Fibrosis, Time, NK, Northwest Biotherapeutics, Data management, CTA, University, Universal Hospital Tirana, Heart failure, Safety, Public health, Biomarker, Head, Therapy, SVP, MD, Immunoglobulin G, Cardiology, ADCC, HER4, Pharmaceutical industry, Vaccine

The Company also announced the submission of the first clinical trial application (CTA) in Europe for its lead oncology program, JK08, and the appointment of Arian Pano, M.D., as Chief Medical Officer.

Key Points: 
  • The Company also announced the submission of the first clinical trial application (CTA) in Europe for its lead oncology program, JK08, and the appointment of Arian Pano, M.D., as Chief Medical Officer.
  • We have made considerable progress this year across our pipeline and remain laser-focused on advancing these important programs to bring differentiated complex biologics to patients with unmet needs, concluded Murphy.
  • In addition, dose-dependent increases in biomarker surrogates of target engagement have been observed across the two completed cohorts.
  • SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases.

China Clopidogrel Investigation Market Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Health, Pharmaceutical, Salubris Pharmaceuticals, Chuang Song Zong Pharmaceutical Co., Ltd., Hangzhou, Platelet, Pulitzer Prize for Investigative Reporting, Dosage form, CAGR, Animal, Fine chemical, Generic drug, Pharmaceutical industry, Sanofi, Clopidogrel, Clopidogrel

The "Investigation Report on Chinese Clopidogrel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on Chinese Clopidogrel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • In addition to Sanofi, the other main manufacturers of Clopidogrel in the Chinese market are Salubris Pharmaceuticals, Lepu Pharmaceutical, and CSPC Ouyi Pharmaceutical.
  • According to this market research, sales revenue of Clopidogrel in China has been decreasing since 2018, sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020.
  • Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term.

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Retrieved on: 
Monday, March 7, 2022
Science, Cardiology, Biotechnology, Research, Oncology, Health, Mental Health, Clinical Trials, Heart failure, Research, Patient, Pharmacokinetics, Degenerative disease, Epidemiology, A, Death, Quality of life, Neurodegeneration, Cohort, Safety, Blood, FDA, G1, HER4, Cleveland Clinic, Cancer, Salubris Pharmaceuticals, HER3, Clinical trial, Mortality, Center, Drug discovery, Groenewegen, Heart failure with preserved ejection fraction, Northwest Biotherapeutics, Therapy, Pharmaceutical industry, Heart, Heart Failure, JK07, Heart Failure, JK07, HEART FAILURE, JK07

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

Key Points: 
  • Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • We are focused on advancing our programs and securing additional funding to progress the development of our portfolio of antibody fusion proteins and other complex biologics.
  • Since its inception, SalubrisBio has built a drug discovery and development platform to address significant unmet medical needs in cardiovascular diseases, cancer and neurodegenerative diseases.
  • SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases.